MRI Study of Subjects With ASD, Their Relatives and TD

Sponsor
Institut National de la Santé Et de la Recherche Médicale, France (Other)
Overall Status
Recruiting
CT.gov ID
NCT05470088
Collaborator
APHP (Other), Institut Pasteur (Industry), Commissariat A L'energie Atomique (Other)
1,000
2
210
500
2.4

Study Details

Study Description

Brief Summary

This project is structured around a central study called "Study of genetic factors involved in autism and related conditions ("Genes and Autism" study, sponsor: INSERM). This study explores clinical and genetic aspects of ASD (autism spectrum disorders) and is complemented with several ancillary studies (such as this one) which will use the data of the main study and will allow an extensive review of phenotypes associated with ASD.

In this ancillary study, we will go on the acquisition of anatomical, diffusion and functional MRI in subjects with ASD, relatives and controls. Our group has already performed several neuroanatomical studies of ASD. IWe recruited since 2010 more than 600 subjects (proponents, relatives and controls) to better understand the implication of brain abnormalities in ASD.

This study involves specialized teams in neuroiamging based at INSERM, NeuroSpin (CEA), Robert Debré Hospital (APHP) and Pasteur Institute

Our main objective is to identify structural, connectivity and functional peculiarities in subjects with ASD

Secondary objectives include:
  • the identification of familial heritability patterns of ASD

  • correlate data obtained in brain imaging with genetic data

  • assess specificity and statistical reproducibility of the obtained results

Condition or Disease Intervention/Treatment Phase
  • Other: Neuroimaging (MRI)

Study Design

Study Type:
Observational
Anticipated Enrollment :
1000 participants
Observational Model:
Case-Control
Time Perspective:
Cross-Sectional
Official Title:
Magnetic Resonance Imaging Neuroanatomical Study of Patients With an Autism Spectrum Disorder, Their Relatives and Typically Developing Subjects.
Actual Study Start Date :
Mar 13, 2022
Anticipated Primary Completion Date :
Sep 13, 2023
Anticipated Study Completion Date :
Sep 13, 2039

Arms and Interventions

Arm Intervention/Treatment
Subjects with Autism Spectrum Disorders

Other: Neuroimaging (MRI)
Multimodal magnetic resonance imaging

Relatives of subjects with Autism Spectrum Disorders

Other: Neuroimaging (MRI)
Multimodal magnetic resonance imaging

Typically developing subjects

Other: Neuroimaging (MRI)
Multimodal magnetic resonance imaging

Outcome Measures

Primary Outcome Measures

  1. 3DT1 MRI derived variables [Day 0]

    Cortical folding Cortical thickness Cortical surface Cortical, white matter and subcortical volumes

  2. Resting state fMRI derived variables [Day 0]

    Whole-brain BOLD signal correlations

  3. Task based fMRI derived variables [Day 0]

    BOLD activation signals BOLD signal correlations

  4. Diffusion MRI derived variables [Day 0]

    Fractional anisotropy and mean diffusivity NODDI derived variables

  5. quantitative T1 and quantitative T2 MRI [Day 0]

    Myelin Water Fraction

Eligibility Criteria

Criteria

Ages Eligible for Study:
24 Months and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • for patients:

  • being included in the main study "C16-89 - Study of genetic factors involved in ASD and related disorders"

  • having an ASD fulfilling DSM-5 diagnostic criteria (APA, 2012). Diagnosis will be done by a clinical expert, with the support of structured instruments (ADI-R, ADOS-2)

  • having at least 24 Months

  • being affiliated with the French health insurance

  • having signed the informed consent (by proposant or by legal tutors if the subject is <18 or under legal custody)

  • for relatives

  • being included in the main study "C16-89 - Study of genetic factors involved in ASD and related disorders"

  • having at least 24 Months

  • being affiliated with the French health insurance

  • having signed the informed consent (by proposant or by legal tutors if the subject is <18 or under legal custody)

  • for controls

  • being included in the main study "C16-89 - Study of genetic factors involved in ASD and related disorders"

  • having at least 24 Months

  • being affiliated with the French health insurance

  • having signed the informed consent (by proposant or by legal tutors if the subject is <18 or under legal custody)

Non-inclusion criteria:
  • for all subjects

  • severe mental retardation (IQ<35 or developmental age<18 months)

  • medical condition (either psychiatric or physical) not compatible with an inclusion

  • MRI counter indication

  • Current pregnancy or breastfeeding, assessed by questionnaire

  • Not willing to be informed of a brain abnormality diagnosed with MRI

  • for the relatives

*discovery of non filiation during the genetic analyses

  • for controls

  • Neurological history (except mental retardation)

  • Personal history of (checked with DIGS for Adults, Diagnostic Interview for Genetic Studies, Numberger et coll., 1994, or Kiddie SADS, Kiddie Schedule for

Disorders and Schizophrenia for School Age Children, Orvaschel et coll., 1982):

schizophrenia, addiction, bipolar disorder, recurrent depression (> 2 episodes lifetime), severe, not stabilized anxiety disorder, history of episodes of epilepsy, significant inflammatory disease of immunosuppressive medication

Exclusion Criteria:
  • for patients: ASD diagnosis not confirmed by assessments after the inclusion

  • for all subjects: discovery of a counter indication to MRI during the exam (e.g. claustrophobia)

Contacts and Locations

Locations

Site City State Country Postal Code
1 NeuroSpin neuroimaging platforme Gif-sur-Yvette France 91191
2 APHP, Hôpital Robert Debré Paris France 75019

Sponsors and Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France
  • APHP
  • Institut Pasteur
  • Commissariat A L'energie Atomique

Investigators

  • Principal Investigator: Richard Delorme, M.D, Ph.D, APHP, France
  • Study Chair: Josselin Houenou, M.D, Ph.D, Institut National de la Santé Et de la Recherche Médicale, France

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Institut National de la Santé Et de la Recherche Médicale, France
ClinicalTrials.gov Identifier:
NCT05470088
Other Study ID Numbers:
  • C16-90
  • 2017-A02356-47
First Posted:
Jul 22, 2022
Last Update Posted:
Aug 4, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Institut National de la Santé Et de la Recherche Médicale, France
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 4, 2022